Investigational Drug Information for AZD-5423
✉ Email this page to a colleague
What is the development status for investigational drug AZD-5423?
AZD-5423 is an investigational drug.
There have been 33 clinical trials for AZD-5423.
The most recent clinical trial was a Phase 3 trial, which was initiated on September 15th 2021.
The most common disease conditions in clinical trials are Lung Neoplasms, Small Cell Lung Carcinoma, and Ovarian Neoplasms. The leading clinical trial sponsors are AstraZeneca, National Cancer Institute (NCI), and Samsung Medical Center.
There are seven US patents protecting this investigational drug and one hundred and fifty-four international patents.
Summary for AZD-5423
| US Patents | 7 |
| International Patents | 154 |
| US Patent Applications | 43 |
| WIPO Patent Applications | 11 |
| Japanese Patent Applications | 4 |
| Clinical Trial Progress | Phase 3 (2021-09-15) |
| Vendors | 28 |
Recent Clinical Trials for AZD-5423
| Title | Sponsor | Phase |
|---|---|---|
| Incidence of COVID-19 Following Vaccination in Botswana Against SARS CoV 2 | AstraZeneca | Phase 3 |
| Incidence of COVID-19 Following Vaccination in Botswana Against SARS CoV 2 | Botswana Ministry of Health | Phase 3 |
| Incidence of COVID-19 Following Vaccination in Botswana Against SARS CoV 2 | Botswana Harvard AIDS Institute Partnership | Phase 3 |
Clinical Trial Summary for AZD-5423
Top disease conditions for AZD-5423
Top clinical trial sponsors for AZD-5423
US Patents for AZD-5423
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| AZD-5423 | ⤷ Try a Trial | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (Sodertalje, SE) | ⤷ Try a Trial |
| AZD-5423 | ⤷ Try a Trial | Chemical compounds | AstraZeneca AB (Sodertalje, SE) | ⤷ Try a Trial |
| AZD-5423 | ⤷ Try a Trial | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (Sodertalje, SE) | ⤷ Try a Trial |
| AZD-5423 | ⤷ Try a Trial | Pharmaceutical product comprising a p38 kinase inhibitor and a second active ingredient | Astrazeneca AB (Sodertalje, SE) | ⤷ Try a Trial |
| AZD-5423 | ⤷ Try a Trial | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | AstraZeneca AB (Sodertalje, SE) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for AZD-5423
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| AZD-5423 | Argentina | AR099177 | 2034-01-24 | ⤷ Try a Trial |
| AZD-5423 | Australia | AU2015208932 | 2034-01-24 | ⤷ Try a Trial |
| AZD-5423 | Australia | AU2017200338 | 2034-01-24 | ⤷ Try a Trial |
| AZD-5423 | Australia | AU2018202956 | 2034-01-24 | ⤷ Try a Trial |
| AZD-5423 | Australia | AU2019202675 | 2034-01-24 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
